Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | CD69 | Q07108 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.40 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13624441 | 0.83 | GSK3B (0.39) | KMT2APTGDR2DAOGSK3BMAPT | |
| SCHEMBL4393404 | 0.78 | ALDH1A1 (0.46) | KMT2AMAPTKDM4EALDH1A1HPGD | |
| SCHEMBL11788276 | 0.77 | TDP1 (0.46) | KMT2APTGDR2DAOALOX15TDP1 | |
| SCHEMBL486042 | 0.74 | DAO (0.48) | KMT2ADAOGSK3BGABBR2GABBR1 | |
| SCHEMBL1024697 | 0.69 | F2 (0.43) | KMT2ADAOGSK3BGABBR2GABBR1 | |
| SCHEMBL12147102 | 0.69 | PTGDR2 (0.62) | PTGDR2TDP1MAPTALDH1A1HPGD | |
| SCHEMBL16434048 | 0.69 | LMNA (0.48) | KMT2APTGDR2ALOX15TDP1MCL1 | |
| SCHEMBL7003234 | 0.68 | F2 (0.42) | KMT2ADAOGSK3BMAPTKDM4E | |
| SCHEMBL25080938 | 0.67 | SMN1; SMN2 (0.39) | KMT2AMAPTHSD17B10 | |
| SCHEMBL341114 | 0.67 | ALOX15 (0.50) | KMT2APTGDR2DAOALOX15TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612075-B2 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2009-11-03 | — | — | US | disclosed |
| EP-1208097-B1 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | AVENTIS PHARMA INC (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2004-05-27 | — | — | US | disclosed |
| US-20040072860-A1 | Piperazin-2-one amides as inhibitors of factor xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-15 | — | — | US | disclosed |
| EP-1322643-A1 | PIPERAZIN-2-ONE AMIDES AS INHIBITORS OF FACTOR XA | Millennium Pharmaceuticals, Inc. (US) | 2003-07-02 | — | — | EP | disclosed |
| EP-1322633-A2 | ARYLOXY ESTER AND ACID COMPOUNDS | Aventis Pharma Deutschland GmbH (DE) | 2003-07-02 | — | — | EP | disclosed |
| EP-1051176-A4 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARM PROD INC (US) | 2002-06-12 | — | — | EP | disclosed |
| EP-1208097-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | Aventis Pharmaceuticals Inc. (US) | 2002-05-29 | — | — | EP | disclosed |
| WO-2002026734-A1 | PIPERAZIN-2-ONE AMIDES AS INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2002-04-04 | — | — | WO | disclosed |
| US-20020013310-A1 | Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2002-01-31 | — | — | US | disclosed |
| EP-1086099-A4 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARM PROD INC (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2001092251-A2 | ARYLOXY ESTER AND ACID COMPOUNDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-12-06 | — | — | WO | disclosed |
| US-6281227-B1 | INHIBITORS OF THE ACTIVITY OF FACTOR XA. | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-08-28 | — | — | US | disclosed |
| CN-1291892-A | Substituted oxoazaheterocyclyl factor Xa inhibitors | AWENTIS PHARMACEUTICAL INC (US) | 2001-04-18 | — | — | CN | disclosed |
| EP-1086099-A1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | Aventis Pharmaceuticals Products Inc. (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-2001007436-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| EP-1051176-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | Aventis Pharmaceuticals Products Inc. (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-2000032590-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-06-08 | — | — | WO | disclosed |
| WO-1999062904-A1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-12-09 | — | — | WO | disclosed |
| WO-1999037304-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | F13B, F9, F11 | KMT2A 2513/4885PTGDR2 936/4885DAO 330/4885 |
| US-20040072860-A1 | Piperazin-2-one amides as inhibitors of factor xa | F2, TFPI, TFPI2 | KMT2A 2284/4885PTGDR2 1058/4885DAO 2086/4885 |
| US-20020013310-A1 | Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds | STS, ARSA, F12 | KMT2A 2583/4885PTGDR2 1242/4885DAO 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.